Don’t Trade in the Dark—Get Your Pre-Market Report Every Day.Join Now
Pharmaceuticals & Biotechnology | Small Cap
Health Score : 5.38Dishman Carbogen Amcis Ltd, operating in the Healthcare Services sector, demonstrates a mixed financial performance. The company shows strong solvency and growth, indicating a solid foundation and expansion in key areas. However, liquidity and efficiency are areas of concern, suggesting challenges in managing short-term obligations and asset utilization. Profitability metrics are also varied, with some positive gross and operating margins offset by negative returns on equity and net margins. The company's coverage ratios are weak, indicating potential difficulties in meeting its interest obligations. Overall, while the company exhibits growth potential and financial stability, it needs to address its liquidity and efficiency challenges to ensure sustained financial health. It's important to consider the unique dynamics of the Healthcare Services industry, which can significantly impact financial ratios.
Health Score : 5.38Dishman Carbogen Amcis Ltd, operating in the Healthcare Services sector, demonstrates a mixed financial performance. The company shows strong solvency and growth, indicating a solid foundation and expansion in key areas. However, liquidity and efficiency are areas of concern, suggesting challenges in managing short-term obligations and asset utilization. Profitability metrics are also varied, with some positive gross and operating margins offset by negative returns on equity and net margins. The company's coverage ratios are weak, indicating potential difficulties in meeting its interest obligations. Overall, while the company exhibits growth potential and financial stability, it needs to address its liquidity and efficiency challenges to ensure sustained financial health. It's important to consider the unique dynamics of the Healthcare Services industry, which can significantly impact financial ratios.
Overall Valuation Score
Markets Depth NSE
Buy Orders
Bid
Quantity
Orders
No buy depth
Total
0
0
Sell Orders
Ask
Quantity
Orders
No sell depth
Total
0
0
Markets Today NSE
High
0.00
Low
0.00
Open
0.00
Close
0.00
Prev Close
0.00
Avg Price
0.00
Volume
0
Last Traded Quantity
0
Last Traded Time
N/A
Price Movement Indicator
Today's Low: 0.00
Today's High: 0.00
P/E RATIO (TTM)
-74.22
Industry Median
30.91
Small Cap Median
28.64
P/E RATIO
29.23
P/B RATIO
0.43
Industry Median
3.69
Small Cap Median
3.11
P/S RATIO
0.97
Industry Median
3.74
Small Cap Median
3.02
Others
PEG RATIO
0.00
EV/EBITDA RATIO
5.98
The Calculations Shown Above Are Based on the Last Traded Price (LTP) of ₹181.83 as on Sep 1, 2026.
Growth Score : 10.00The growth ratios paint a promising picture of the company's expansion. The company has a strong growth position. This growth momentum positions the company favorably for future success. On the other hand, the company needs to sustain its growth position.
Revenue Growth RateExcellentOperating Profit Growth RateExcellentEarnings Per Share (EPS) GrowthExcellentAsset Growth RateExcellentNet Income Growth RateExcellent| Growth Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue Growth Rate | 11.98 | 12.7 | 8.41 | 3.67 | 8.11 |
| Operating Profit Growth Rate | 20.8 | 0.3 | -13.86 | 63.99 | 20.68 |
| Earnings Per Share (EPS) Growth | 110.92 | -265.22 | -415.26 | 102.15 | 2861.9 |
| Asset Growth Rate | 3.33 | 9.32 | 1.4 | 4.35 | 19.39 |
| Net Income Growth Rate | 110.91 | -266.67 | -410 | 101.96 | 3133.33 |
Revenue Growth Rate
Operating Profit Growth Rate
Earnings Per Share (EPS) Growth
Asset Growth Rate
Net Income Growth Rate
No Peer Data Is Available at This Moment.
0 Credits RemainingUnlock Deep Technical Insights in Seconds Only with Dhanarthi AI
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Strong Bearish
Market Sentiment
Analysis Driven By 26 Technical Indicators From The 1 Hour Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Strong Bearish
Momentum Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bearish
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Analyzing moving average trends and crossovers. Green/Red badges indicate if the current condition passes or fails.
Comparing stock price performance (normalized) against benchmark indices over time.
Recent daily trading volume represented as a bar chart, alongside historical averages.
Current closing price relative to the 52-week highest and lowest prices.
No Stock Reports Available at This Moment.
Dishman Carbogen Amcis Ltd (DCAL) is a global integrated Contract Development and Manufacturing Organization (CDMO) and supplier of intermediates, Active Pharmaceutical Ingredients (APIs), and quaternary ammonium compounds. It serves pharmaceutical, biopharmaceutical, and specialty chemical industries worldwide, leveraging its strong R&D and manufacturing capabilities.
P/E Ratio (TTM): Price to Earnings ratio shows how much an investor pays for every rupee of the company's earnings. Dishman Carbogen Amcis Ltd's P/E ratio (TTM) is -74.22, compared to the industry median of 30.91 and large cap median of 28.64.
P/B Ratio: Price to Book ratio compares a company's market price to its book value per share. Dishman Carbogen Amcis Ltd's P/B ratio is 0.43, compared to the industry median of 3.69 and large cap median of 3.11.
P/S Ratio: Price to Sales ratio compares a company's market value to its total revenue. Dishman Carbogen Amcis Ltd's P/S ratio is 0.97, compared to the industry median of 3.74 and large cap median of 3.02.
PEG Ratio: PEG ratio adjusts the P/E ratio for expected earnings growth. Dishman Carbogen Amcis Ltd's PEG ratio is N/A.
EV/EBITDA Ratio: This ratio compares a company's enterprise value to its earnings before interest, tax, depreciation, and amortization. Dishman Carbogen Amcis Ltd's EV/EBITDA ratio is 5.98.
Return on Equity (ROE): ROE measures how much profit a company generates from shareholders' invested capital. Dishman Carbogen Amcis Ltd's ROE is 1.45%.
Return on Assets (ROA): ROA measures how efficiently a company converts its assets into net profit. Dishman Carbogen Amcis Ltd's ROA is 4.75%.
Return on Capital Employed (ROCE): ROCE measures how efficiently a company generates profit from all the capital it employs. Dishman Carbogen Amcis Ltd's ROCE is 3%.
Operating Margin: Operating margin shows what percentage of revenue remains after covering operating expenses. Dishman Carbogen Amcis Ltd's operating margin is 19.30%.
Net Margin: Net margin shows what percentage of revenue converts into final net profit. Dishman Carbogen Amcis Ltd's net margin is 3.31%.
Current Ratio: The current ratio measures a company's ability to pay short-term liabilities using short-term assets. Dishman Carbogen Amcis Ltd's current ratio is 0.93.
Debt to Equity Ratio: This ratio shows the proportion of debt a company uses relative to shareholders' equity. Dishman Carbogen Amcis Ltd's debt-to-equity ratio is 0.28.
Interest Coverage Ratio: This ratio shows how easily a company can pay interest on its outstanding debt from its operating earnings. Dishman Carbogen Amcis Ltd's interest coverage ratio is 1.60.
Dividend Per Share (DPS): DPS shows the total dividend paid per share in the latest financial year. Dishman Carbogen Amcis Ltd's DPS is ₹0.
Earnings Per Share (EPS): EPS shows how much profit is allocated to each outstanding share. Dishman Carbogen Amcis Ltd's EPS is 2861.90.
(Source line: "Ratios as of 25 Sept 2026, based on last traded price of ₹181.83. Data sourced from BSE/NSE Exchange Filings & Public Terminal Data.")
Founded: 1983 (as Dishman Pharmaceuticals and Chemicals Ltd.)
Headquarters: Ahmedabad, Gujarat
Core Offerings: Contract Development and Manufacturing (CDMO), Active Pharmaceutical Ingredients (APIs), Advanced Intermediates, Quaternary Ammonium Compounds (Quats), Vitamin D & Analogues
Stock Listing: NSE (DCAL), BSE (540701)
Promoter: J.R. Vyas Family
Dishman Pharmaceuticals and Chemicals Ltd. was incorporated in 1983, establishing its first manufacturing facility in Bavla, Gujarat in 1997. A significant milestone was the acquisition of Swiss-based Carbogen Amcis AG in 2006, which greatly expanded its global CDMO footprint and capabilities. The company was subsequently renamed Dishman Carbogen Amcis Ltd (DCAL) in 2017, reflecting its integrated global operations in CDMO and specialty chemicals.
| Segment Name | Revenue % | EBITDA |
|---|---|---|
| Contract Research and Manufacturing Services (CRAMS) | 66% | Operating Profit |
| Marketable Molecules | 34% | Operating Profit |
Contract Research and Manufacturing Services (CRAMS / CDMO): Offers comprehensive services from process development to commercial manufacturing for pharmaceutical and biopharmaceutical companies, specializing in complex APIs, highly potent APIs (HPAPIs), and clinical trial materials.
Marketable Molecules: Produces and supplies a range of specialized products including Active Pharmaceutical Ingredients (APIs), advanced intermediates, quaternary ammonium compounds (Quats) for diverse applications, and Vitamin D and its analogues for pharmaceutical and nutritional sectors.
J.R. Vyas - Chairman & Managing Director. He is the founder of Dishman Group and brings over four decades of experience in the chemical and pharmaceutical industries, steering the company's strategic growth and global presence.
['Carbogen Amcis AG (Switzerland)', 'Carbogen Amcis SAS (France)', 'Carbogen Amcis LLC (USA)', 'Dishman Netherlands BV (Netherlands)', 'Dishman (China) Specialty Chemical Co. Ltd. (China)']
Acquisition of Carbogen Amcis AG in 2006 significantly transformed the company's business model and global presence. No major recent capital actions (rights/bonus issues) on record in the last five years.
The Dishman Carbogen Amcis Ltd share price today is ₹181.83 on NSE (DCAL), as of 26 Sept 2026.
As of 25 Sept 2026, Dishman Carbogen Amcis Ltd share price is ₹181.83, with previous close ₹181.83. Today's range is ₹181.83 to ₹181.83. The 52-week range is ₹128.50 to ₹274.30.
As of today, Dishman Carbogen Amcis Ltd's market cap is ₹2,849.28 crore (Small Cap).
Dishman Carbogen Amcis Ltd's current P/E ratio is -74.22, compared to the PHARMACEUTICALS & BIOTECHNOLOGY sector average of 33.
Dishman Carbogen Amcis Ltd's current P/B ratio is 0.43.
Dishman Carbogen Amcis Ltd's current dividend yield is N/A. Last dividend of ₹0.20 per share was declared on 14-Sep-2023.
Dishman Carbogen Amcis Ltd's EPS (TTM) is ₹2861.90.
Dishman Carbogen Amcis Ltd (DCAL) is a global integrated Contract Development and Manufacturing Organization (CDMO) and supplier of intermediates, Active Pharmaceutical Ingredients (APIs), and quaternary ammonium compounds. It serves pharmaceutical, biopharmaceutical, and specialty chemical industries worldwide, leveraging its strong R&D and manufacturing capabilities.
Dishman Carbogen Amcis Ltd is promoted by J.R. Vyas Family, holding 59.32% as of 25 Sept 2026.
Dishman Carbogen Amcis Ltd is listed on NSE (DCAL) and BSE (540701). Its next quarterly results are expected on August 2024 (Q1 FY25).
Adjusted Earnings Per Share (Adjusted EPS)
Cash Earnings Per Share (Cash EPS)
